Pliant Therapeutics Inc Stock News

Activities supporting the close out of BEACON-IPF continue; topline data  expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to  support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology comp...

-  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025.

NEW YORK CITY, NY / ACCESS Newswire / April 5, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partne...

Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash reserves. Tang's history of acquiring biotechs at a discount suggests a potential profitable takeover of PLRX, despite management's defensive "poi...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-933...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options